Bimekizumab (Bimzelx) is an anti‐IL‐17A and ‐17F monoclonal antibody for the treatment of moderate to severe plaque psoriasis. This article summarises its efficacy, adverse effects and place in therapy.
{"title":"Bimekizumab for the treatment of plaque psoriasis","authors":"S. Chaplin","doi":"10.1002/psb.2003","DOIUrl":"https://doi.org/10.1002/psb.2003","url":null,"abstract":"Bimekizumab (Bimzelx) is an anti‐IL‐17A and ‐17F monoclonal antibody for the treatment of moderate to severe plaque psoriasis. This article summarises its efficacy, adverse effects and place in therapy.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91161244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Idiopathic pulmonary fibrosis (IPF) is a form of idiopathic interstitial pneumonia that currently carries a poor prognosis and remains incurable, though antifibrotic therapy can slow disease progression. This article provides an overview of its diagnosis, treatment and the management of co‐morbidities.
{"title":"Diagnosis and management of idiopathic pulmonary fibrosis","authors":"Vijay Joshi, Zaneeta Nagji","doi":"10.1002/psb.1998","DOIUrl":"https://doi.org/10.1002/psb.1998","url":null,"abstract":"Idiopathic pulmonary fibrosis (IPF) is a form of idiopathic interstitial pneumonia that currently carries a poor prognosis and remains incurable, though antifibrotic therapy can slow disease progression. This article provides an overview of its diagnosis, treatment and the management of co‐morbidities.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"2004 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88336950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NICE has recently published a guideline on the safe prescribing and withdrawal of medicines associated with dependence or withdrawal symptoms (NG215), including benzodiazepines, Z‐drugs, opioids, gabapentinoids and antidepressants. This article summarises the guidance, which recommends a supportive and collaborative approach.
{"title":"Safe prescribing and withdrawal of dependence‐forming medicines","authors":"S. Chaplin","doi":"10.1002/psb.2002","DOIUrl":"https://doi.org/10.1002/psb.2002","url":null,"abstract":"NICE has recently published a guideline on the safe prescribing and withdrawal of medicines associated with dependence or withdrawal symptoms (NG215), including benzodiazepines, Z‐drugs, opioids, gabapentinoids and antidepressants. This article summarises the guidance, which recommends a supportive and collaborative approach.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78930040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The Diabetes UK Professional Conference 2022 was held online in March, covering a wide range of issues relevant to primary care, including recognising type 1 diabetes in children, managing insulin pump failure, and updated NICE guidance on type 2 diabetes. Joy Ogden presents some of the conference highlights.
{"title":"Diabetes UK Professional Conference 2022 highlights","authors":"J. Ogden","doi":"10.1002/psb.1999","DOIUrl":"https://doi.org/10.1002/psb.1999","url":null,"abstract":"The Diabetes UK Professional Conference 2022 was held online in March, covering a wide range of issues relevant to primary care, including recognising type 1 diabetes in children, managing insulin pump failure, and updated NICE guidance on type 2 diabetes. Joy Ogden presents some of the conference highlights.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82291079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The introduction of new and effective direct‐acting antivirals has revolutionised the treatment of hepatitis C over the last decade. Part 2 of this two‐part series on the management of hepatitis C provides an overview of these new treatments, as well as discussing hepatitis C diagnosis and harm‐reduction strategies.
{"title":"Hepatitis C: diagnosis, treatment and harm‐reduction strategies","authors":"G. Parsons","doi":"10.1002/psb.2001","DOIUrl":"https://doi.org/10.1002/psb.2001","url":null,"abstract":"The introduction of new and effective direct‐acting antivirals has revolutionised the treatment of hepatitis C over the last decade. Part 2 of this two‐part series on the management of hepatitis C provides an overview of these new treatments, as well as discussing hepatitis C diagnosis and harm‐reduction strategies.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"40 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89582660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CRISPR is a gene editing technique that has revolutionised research and has the potential to transform the treatment of many diseases. This article discusses the principles of the technique, its therapeutic applications and potential safety issues.
{"title":"CRISPR gene editing: a revolution in progress","authors":"M. Greener","doi":"10.1002/psb.1990","DOIUrl":"https://doi.org/10.1002/psb.1990","url":null,"abstract":"CRISPR is a gene editing technique that has revolutionised research and has the potential to transform the treatment of many diseases. This article discusses the principles of the technique, its therapeutic applications and potential safety issues.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"79 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86517469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tralokinumab (Adtralza) is a new anti‐IL‐13 monoclonal antibody for the treatment of moderate to severe atopic dermatitis. This article summarises its administration, clinical trial efficacy and adverse effects.
{"title":"Tralokinumab for the treatment of atopic dermatitis","authors":"S. Chaplin","doi":"10.1002/psb.1995","DOIUrl":"https://doi.org/10.1002/psb.1995","url":null,"abstract":"Tralokinumab (Adtralza) is a new anti‐IL‐13 monoclonal antibody for the treatment of moderate to severe atopic dermatitis. This article summarises its administration, clinical trial efficacy and adverse effects.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79855552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shared decision making (SDM) between patients and healthcare professionals about tests, treatments and care reflects many NHS values and firmly establishes patients at the centre of their healthcare. This article considers the benefits of successful implementation of SDM alongside some of the key challenges of risk communication.
{"title":"Risk communication: a pillar of shared decision making","authors":"D. Laight","doi":"10.1002/psb.1993","DOIUrl":"https://doi.org/10.1002/psb.1993","url":null,"abstract":"Shared decision making (SDM) between patients and healthcare professionals about tests, treatments and care reflects many NHS values and firmly establishes patients at the centre of their healthcare. This article considers the benefits of successful implementation of SDM alongside some of the key challenges of risk communication.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"66 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76514435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：